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Background: To examine the efficacy of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit/
hyperactivity disorder (ADHD) who remained symptomatic (ADHD Rating Scale IV [ADHD-RS-IV] total score >18) on
amphetamine (AMPH) therapy (mixed AMPH salts and/or d-AMPH formulations) prior to enrollment in a 4-week
placebo-controlled LDX trial vs the overall study population. In these post hoc analyses from a multicenter,
randomized, double-blind, forced-dose titration study, clinical efficacy of LDX (30-70 mg/d) in adults with ADHD
receiving AMPH treatment at screening vs the overall study population was evaluated. ADHD symptoms were
assessed using the ADHD-RS-IV with adult prompts at screening, baseline (after prior treatment washout), and
endpoint. Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings,
and electrocardiogram.
Results: Of 414 participants (62, placebo; 352, LDX) included in the overall study population, 41 were receiving
AMPH therapy at screening (2, placebo; 39, LDX); mean AMPH dose was 35.0 and 34.1 mg/d for participants in
placebo and all LDX groups, respectively. Of the 41 participants, 36 remained symptomatic (ADHD-RS-IV >18) at
screening despite receiving AMPH. For the 36 participants in the placebo (n = 2) and LDX (n = 34) groups,
respectively, at endpoint, mean change from screening ADHD-RS-IV total scores were -5.5 and -14.8 and from
baseline scores were -13.5 and -17.8. For the overall study population, endpoint mean change from baseline ADHD-
RS-IV total scores were -7.8 for placebo and -17.5 for LDX. In the prior AMPH subgroup, 2/2 (100.0%) in the placebo
group and 22/39 (56.4%) participants in the LDX (all doses) group reported any TEAE. Events that occurred in ≥5%
for LDX were dry mouth (5/39; 12.8%), headache (5/39; 12.8%), fatigue (3/39; 7.7%), insomnia (3/39; 7.7%), decreased
appetite (2/39; 5.1%), and nausea (2/39; 5.1%). None of these events occurred in the 2 placebo patients with prior
AMPH use.
Conclusion: In these post hoc analyses, adults with significant baseline ADHD symptoms despite adequate AMPH
treatment dose showed similar improvements in ADHD symptoms with LDX treatment as the overall study
population. Prospective studies are needed to confirm these findings. The safety profile of LDX in the overall study
population was consistent with long-acting psychostimulant use.
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Attention-deficit/hyperactivity disorder (ADHD) affects
approximately 4.4% of adults in the United States [1].
Currently, psychostimulants, both amphetamines (AMPH)
and methylphenidate (MPH), are considered first-line
ADHD pharmacotherapy in adults [2-4]. Clinically non-
responsive patients treated with one psychostimulant
will often obtain an improved clinical response when
switched to another psychostimulant class; possibly be-
cause classes may differ in mechanisms of action [5]. As
reviewed by Arnold and colleagues, AMPH and MPH
are reuptake inhibitors of norepinephrine and dopamine
(DA) [5]. However, AMPH also stimulates neurotrans-
mitter release from presynaptic receptors.
Moreover, it is observed in psychiatry that, when
patients exhibit efficacy or tolerability concerns while on
a treatment, it is not uncommon in clinical practice (e.g.,
depression treatment) for a patient to be switched to a
different medication within the same class [6,7]. In
ADHD treatment and management, this has included
switching from an immediate-release or short-acting
formulation to a long-acting formulation [8,9], or from a
racemic mixture to a single enantiomer formulation
(e.g., d-MPH) [10].
The AMPH class of psychostimulants comprises short-
and long-acting formulations of mixed AMPH salts
(MAS) and MAS extended release (MAS XR), respect-
ively, and d-AMPH formulations, including short-acting
d-AMPH and long-acting d-AMPH (d-AMPH-ER), and
the prodrug lisdexamfetamine dimesylate (LDX). LDX is
a long-acting prodrug stimulant indicated for ADHD
treatment in children (6 to 12 years), adolescents (13 to
17 years), and adults [11]. The inactive prodrug is con-
verted, primarily in the blood, to l-lysine and therapeutic-
ally active d-AMPH [12]. MAS XR is a once-daily beaded
formulation, also indicated for ADHD treatment in chil-
dren (6 to 12 years), adolescents (13 to 17 years), and
adults [13]. Overall, studies have demonstrated the effect-
iveness and safety of LDX and MAS XR in adults with
ADHD [14-18]. However, a qualitative comparison in a
matched-group post hoc analysis suggested that LDX
provided greater improvement in ADHD symptoms [16].
Unlike LDX, the pharmacokinetic profile of MAS XR is
altered by gastrointestinal pH variations, as assessed by
coadministration with a proton pump inhibitor that
reduces stomach acid [19].
A PubMed literature search of relevant papers
produced none that systematically assessed treatment
response in patients switched between different formula-
tions of the same class of stimulant (e.g., from one MPH
or AMPH formulation to another). Therefore, a study
assessing treatment effects of a more recent psychosti-
mulant formulation in adults who remain symptomatic
while using another psychostimulant formulation maybe useful to clinicians choosing between treatment options
for adults with ADHD.
The objectives of these post hoc analyses were to as-
sess the efficacy of LDX in adults with ADHD who
remained symptomatic on AMPH therapy (various for-
mulations) prior to enrollment vs the overall study
population in a 4-week, placebo-controlled, LDX trial.
Comparing symptomatic recent and prior AMPH users
to the overall study population of adults with ADHD
treated with LDX can aid clinicians in determining if
LDX may be a viable treatment option after another
AMPH medication has been used with suboptimal treat-
ment response.
Methods
Study design and participants
This was a multicenter, randomized, double-blind,
forced-dose titration, 4-week study that evaluated effi-
cacy of LDX (30, 50, and 70 mg/d) vs placebo in adults
(18 to 55 years) with ADHD. The study was performed
in accordance with the Declaration of Helsinki and the
International Conference on Harmonisation Guidelines
for Good Clinical Practice. All participants provided
written informed consent and Institutional Review Board
approval was obtained at all study sites prior to study
conduct. Institutional Review Boards/Ethics Committees
approving the study were Aspire IRB, 9320 Fuerte Dr,
Suite 105, La Mesa, CA 91941 (multiple study sites);
Duke University Medical Center IRB, Hock Plaza, 2424
Erwin Rd, Suite 405, Durham, NC 27705; Office of Insti-
tutional Review (UHC IRB) University Hospitals of
Cleveland, 11100 Euclid Ave, Lakeside 1400, Cleveland,
OH 44106-7061; Partners Human Research Committee,
116 Huntington Ave, Suite 1002, Boston, MA 02116;
Subcommittee for Human Studies (SHS), 423 E 23rd St,
18S, New York, NY 10010; UCSF Committee on Human
Research, 3333 California St, San Francisco, CA 94143-
0310; University of California, Irvine, Institutional Review
Board, Office of Research Administration, 300 University
Tower, Irvine, CA 92697; Western Institutional Review
Board (WIRB), 3535 Seventh Ave, SW, Olympia, WA
98502; and Yale University School of Medicine Human
Investigation Committee (HIC), 47 College St, Suite 208,
PO Box 208010, New Haven, CT 06520. The method-
ology and results of the primary and secondary analyses
from this study have been reported elsewhere [20]. The
study included participants on AMPH formulations, in-
cluding MAS, MAS XR, and d-AMP (d-AMPH spansule
and short-acting d-AMPH) at screening and who, at
screening, remained symptomatic on their prior treat-
ment. Post hoc analyses of these participants were con-
ducted and are reported here. Participants may have
previously been on more than one type of AMPH.
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sis, by Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition, Text Revision [21] (DSM-IV-TR)
criteria and an ADHD Rating Scale IV [22] (ADHD-RS-IV)
with adult prompts [23] total score of ≥28 at baseline.
Primary efficacy assessments
The primary efficacy measure was the ADHD-RS-IV
with adult prompts that assessed ADHD symptoms at
screening, baseline (after washout of prior treatment),
and endpoint. Endpoint was defined as the last postran-
domization treatment week with a valid ADHD-RS-IV
score. The primary efficacy endpoint was the mean
change from baseline to endpoint in ADHD-RS-IV total
score in the overall efficacy or intention-to-treat (ITT)
population (all randomized and treated participants who
had a baseline ADHD-RS-IV score and at least one post-
randomization ADHD-RS-IV score).
Other efficacy measures
The Clinical Global Impressions [24] (CGI) scale evaluated
global ADHD symptom illness severity and improvement.
CGI-Severity (CGI-S) was assessed at baseline using a
7-point scale with scores ranging from 1 (normal, not at
all ill) to 7 (among the most extremely ill). The CGI-Im-
provement (CGI-I) scale was assessed at each postbaseline
visit also on a 7-point scale with scores ranging from 1
(very much improved) to 7 (very much worse).
Post hoc assessments
The prior AMPH subgroup was defined as all participants
who took AMPH products with a stop date on or after
the screening date. For purposes of this post hoc analysis,
an ADHD-RS-IV total score >18 at screening in the prior
AMPH subgroup was considered a suboptimal level of
symptom control. ADHD symptom items are rated on a
4-point scale, which consists of scores of 0 (never or
rarely), 1 (sometimes), 2 (often), and 3 (very often) [22].
An ADHD-RS-IV total score of ≤18 (an average score of
1 per item for the 18-item scale) has been used to define
symptomatic remission in combined-type ADHD [25]. As
reviewed by Steele and colleagues, when individuals are
treated (with or without medication), symptomatic remis-
sion in ADHD should be defined as a “loss of diagnostic
status, minimal or no symptoms, and optimal function-
ing” [26]. Moreover, on most standardized questionnaires,
symptomatic remission can be “operationalized as a mean
total score of ≤1” for each item or an ADHD-RS-IV total
score of ≤18.
Safety assessments
Safety assessments in the overall safety population included
treatment-emergent adverse events (TEAEs), vital signs,
laboratory findings, and electrocardiogram (ECG).Statistical analysis
Descriptive statistics were used to assess efficacy out-
comes in the prior AMPH subgroup. No comparative
statistical analyses were conducted between the prior
AMPH-treated subgroup and the overall study popula-
tion since the study was not prospectively designed to
assess these comparisons. Based on established criteria
[26,27], clinical response was defined as a change in
ADHD-RS-IV total score of ≥30% from baseline and a
CGI-I score of 1 or 2. Symptomatic remission, a measure
of optimal symptom control, was defined as a postbase-
line ADHD-RS-IV total score ≤18.
The overall safety population comprised all partici-
pants enrolled and randomized who received treatment.
TEAEs were defined as events with onset postrandomi-
zation (i.e., first treatment date).
Results
Disposition
Of 420 participants randomized, 414 (62 receiving
placebo, 352 LDX) were included in the efficacy popula-
tion, 71 of 420 (16.9%) were discontinued, and 41 of
414 (9.9%) were receiving AMPH at screening. Of the
41 prior AMPH-treated participants, 2 were randomized
to placebo and 39 were randomized to LDX (30 mg/d
[n = 11], 50 mg/d [n = 16], and 70 mg/d [n = 12]). In
the placebo group, 1 participant was treated with MAS
and 1 with MAS XR. In the LDX (all doses) group,
11 participants were previously treated with MAS, 27
with MAS XR, and 2 with d-AMPH. Thirty-six (87.8%)
of 41 participants remained symptomatic (ADHD-RS-IV
>18) at screening.
Demographics and baseline characteristics (Table 1)
The mean (standard deviation [SD]) ADHD-RS-IV total
score at screening for the prior AMPH subgroup was 39.3
(7.0) for placebo and 41.0 (5.7) for LDX. Mean (SD) AMPH
doses were 35.0 (7.1) mg/d for those randomized to the pla-
cebo group and 30.0 (8.9), 38.4 (17.7), and 32.2 (22.2) mg/d
for those randomized to the 30-, 50-, and 70-mg/d LDX
groups, respectively. Moreover, duration of prior AMPH
exposure was reported in the range of approximately
2 weeks to 13 years; only 1 participant was treated for
<4 weeks. Two patients reported MAS doses of <20 mg/d.
Primary efficacy measures
At endpoint, change from baseline in mean (SD)
ADHD-RS-IV total scores for LDX-treated participants
was similar in AMPH groups and the overall study
groups (Figure 1). Prior AMPH nonresponders (ADHD-
RS-IV total score >18 at screening) in the placebo group
(n = 2) had baseline mean (SD) ADHD-RS-IV total score
of 41.0 (5.66) and change from baseline was -13.5 (4.95).
In the placebo group of the overall efficacy population
Table 1 Demographics and baseline characteristics of the prior AMPH subgroup (n = 41) and overall safety population
(n = 420)
Variable, n (%) Prior AMPH subgroup Overall safety population
Placebo LDX (all doses) Placebo LDX (all doses)
n = 2 n = 39 n = 62 n = 358
Sex Male 0 20 (51.3) 32 (51.6) 196 (54.7)
Female 2 (100.0) 19 (48.7) 30 (48.4) 162 (45.3)
Race White 1 (50.0) 38 (97.4) 48 (77.4) 301 (84.1)
Non-white 1 (50.0) 1 (2.6) 14 (22.6) 57(15.9)
Ethnicity Hispanic/Latino 0 1 (2.6) 6 (9.7) 34 (9.5)
Non-Hispanic/Non-Latino 2 (100.0) 38 (97.4) 56 (90.3) 324 (90.5)
CGI-S at baseline Moderately ill 1 (50.0) 12 (30.8) 27 (43.5) 115 (32.1)
Markedly ill 1 (50.0) 17 (43.6) 25 (40.3) 195 (54.5)
Severely/extremely ill 0 10 (25.6) 10 (16.1) 48 (13.4)
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was 39.4 (6.42) and change from baseline was -7.8
(9.28). Because of the small number of participants in
the placebo-treated prior AMPH nonresponders group (n
= 2), no comparisons between placebo and LDX AMPH
nonresponders subgroups were warranted.
Other efficacy measures
The mean (SD) CGI scores were comparable between the
prior AMPH subgroup and overall efficacy population in
the LDX-treated groups (Table 2). At all time points
assessed, the percentage of clinical responders and symp-
tomatic remitters was comparable in both LDX groups
(Figures 2a and 2b). For 2 participants in the placebo-trea-
ted prior AMPH subgroup, 1 (50.0%) achieved clinical re-
sponse at week 1 through 4 and at endpoint; and 1 (50.0%)Figure 1 Mean (SD) ADHD-RS-IV total scores for prior AMPH LDX-treaachieved symptomatic remission at week 2 only. For parti-
cipants in the overall efficacy population receiving placebo
(n = 62), the proportion achieving clinical response ranged
from 11.3% at week 1 to 27.4% at week 4 and 29.0% at
endpoint; the proportion achieving symptomatic remission
ranged from 1.6% at week 1 to 11.3% at week 3 and 11.3%
at endpoint.
Safety
In the prior AMPH subgroup, 2 of 2 (100.0%) in the pla-
cebo group and 22 of 39 (56.4%) participants in the LDX
(all doses) group reported any TEAE (Table 3). For those
receiving LDX in this subgroup, TEAEs with ≥5% fre-
quency were dry mouth (5/39; 12.8%), headache (5/39;
12.8%), fatigue (3/39; 7.7%), insomnia (3/39; 7.7%),
decreased appetite (2/39; 5.1%), and nausea (2/39; 5.1%).ted subgroup and overall efficacy population.
Table 2 Mean (SD) CGI-S and CGI-I scores for prior AMPH subgroup and overall efficacy population
Variable Mean (SD) CGI scores
Prior AMPH subgroup Overall efficacy population
Placebo (n = 2) LDX (n = 39) Placebo (n = 62) LDX (n = 352)
CGI-S (Baseline) 4.5 (0.71) 4.9 (0.76) 4.7 (0.73) 4.8 (0.65)
CGI-I (Endpoint) 2.5 (0.71) 2.4 (1.11) 3.2 (1.19) 2.4 (1.07)
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to placebo; therefore, describing “common” TEAEs is
not appropriate, but neither placebo participant experi-
enced one of the TEAEs common in the LDX group. All
TEAEs in all prior AMPH users were of mild to moder-
ate severity and there were no serious TEAEs.
In the overall safety population, 36 of 62 (58.1%) in the
placebo group and 282 of 358 (78.8%) participants in the
LDX (all doses) group reported any TEAE (Table 3). The
majority of TEAEs were mild to moderate in severity.
Twenty-two of 420 (5.2%) participants were discontinued
due to TEAEs in the overall safety population. In this
population, there were no deaths, and 2 of 420 (0.5%)
participants had serious AEs (leg injury due to motor ve-
hicle accident [LDX 30 mg/d group] and postoperative
knee pain [LDX 70 mg/d group]). Both reported seriousFigure 2 Percentage of a) clinical responders and b) symptomatic rem
total score of ≥30% from baseline and a CGI-I score of 1 or 2. Symptom
score of ≤18.AEs were considered not treatment-related, and partici-
pants were discontinued.
At endpoint for the overall safety population, small
mean increases in vital signs (systolic and diastolic blood
pressure) from baseline were not statistically significant
vs placebo. At endpoint for pulse, the slight mean differ-
ence vs placebo was significant (P = .0018). There were
no significant meaningful changes in QTcF interval data
from baseline between the placebo and LDX groups.
Discussion
In these post hoc analyses, adults with significant base-
line ADHD symptoms in the prior AMPH group, despite
adequate mean AMPH treatment dose and duration of
prior treatment (only 1 participant was treated for
<4 weeks), showed improvements in symptoms withitters. Note: Clinical response was defined as a change in ADHD-RS-IV
atic Remission was defined as a post baseline ADHD-RS-IV total
Table 3 Common TEAEs with frequency ≥5% in the LDX (all doses) group and greater than placebo
Preferred terminology (MedDRA 9.1) Participants, n (%)
Prior AMPH subgroup Overall safety population
Placebo
n = 2
LDX (All Doses) Placebo
n = 62
LDX (All Doses)
n = 39 n = 358
All TEAEs 2 (100) 22 (56.4) 36 (58.1) 282 (78.8)
Anorexia 0 0 0 18 (5.0)
Anxiety 0 1 (2.6) 0 21 (5.9)
Decreased appetite 0 2 (5.1) 1 (1.6) 95 (26.5)
Diarrhea 0 0 0 24 (6.7)
Dry mouth 0 5 (12.8) 2 (3.2) 92 (25.7)
Fatigue 0 3 (7.7) 3 (4.8) 17 (4.7)
Headache 0 5 (12.8) 8 (12.9) 74 (20.7)
Initial insomnia 0 1 (2.6) 2 (3.2) 18 (5.0)
Insomnia 0 3 (7.7) 3 (4.8) 69 (19.3)
Irritability 0 1 (2.6) 4 (6.5) 22 (6.1)
Nausea 0 2 (5.1) 0 25 (7.0)
Upper respiratory tract infection 0 1 (2.6) 3 (4.8) 20 (5.6)
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Improvement in ADHD symptoms in LDX-treated adults
was similar in the prior AMPH subgroup and overall effi-
cacy population. Moreover, global severity at baseline
and global symptom improvement with LDX treatment
were comparable across all treatment groups in the prior
AMPH subgroup and overall efficacy population.
One study suggests that, although psychostimulants
(both AMPH and MPH) are effective in ADHD manage-
ment, some participants responded better to one type of
psychostimulant than to the other [28]. However, results
of studies that assess treatment response after switching
between agents in the same class are few. A comparative
review of psychostimulants suggests that many studies
assessing differences between psychostimulants do not
show comparisons at the individual participant level [5].
Thus, it is unknown if patient variability in terms of
prior treatment history may affect response to current
treatment.
This study suggests a differential response to various
ADHD formulations within the same class of psycho-
stimulants may occur, as indicated by the improved clin-
ical response with LDX treatment in participants who
had significant ADHD symptoms despite prior AMPH
therapy. Although conducted in animals with results that
may not apply to humans, a study by Joyce et al sup-
ports this contention; potential variability in response
based on formulation differences among the same
AMPH class of psychostimulants was suggested by dif-
ferential response in AMPH-evoked DA release with
MAS (racemic mixture of 76% d-AMPH and 24%
l-AMPH salts), d-AMPH, and d, l-AMPH in the rat stri-
atum [29].Such variations in neurotransmitter release based
on the differing formulations of the same class of
psychostimulant may play a pivotal role in intrapatient
variability to treatment response. LDX, which is a pro-
drug of d-AMPH covalently bound to therapeutically
inactive l-lysine, has demonstrated consistent and low
inter-and intrapatient pharmacokinetic variability in
d-AMPH mean observed maximum drug concentration
and area under the concentration-time curve from time
zero to infinity, as well as consistent delivery of d-AMPH
in adults [30]. Although a small amount of LDX is hydro-
lyzed to d-AMPH in the gastrointestinal tract, the con-
version into active d-AMPH occurs primarily in the
blood. The LDX conversion to d-AMPH is unlikely to be
affected by gastrointestinal pH and variations in normal
gastrointestinal transit times [31,32].
Another open-label, adult study that assessed LDX and
MAS XR pharmacokinetics, alone or in combination with
omeprazole (proton pump inhibitor) demonstrated that
MAS XR-treated participants on omeprazole experienced
a shortened time to maximum drug concentration (Tmax)
of ≥1 hour in more than 50% of participants vs MAS-XR
alone. However, LDX combination therapy with omepra-
zole resulted in shortened Tmax in only 25% of partici-
pants vs LDX alone [19]. Moreover, the study indicated
that the distribution around the median d-AMPH Tmax
for LDX was unaffected by omeprazole administration,
although for MAS XR the dispersion was compressed.
These aforementioned study data suggest a variable phar-
macokinetic response even among the same class of
psychostimulants. Data in animal models suggest that
amphetamine formulations may differ in their pharmaco-
dynamic effects as well. In rats administered equivalent
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mine release and in locomotor activity were lower in peak
effect but more sustained with LDX vs d-AMPH [33].
A post hoc comparative qualitative analysis, using
groups that were matched based on treatment duration,
baseline ADHD symptom severity, and approximately
equivalent AMPH doses of LDX and MAS XR in adults
with ADHD from 2 similar short-term trials, found that
both psychostimulants demonstrated efficacy vs placebo.
Safety profiles were consistent with psychostimulant use
[16]. However, this qualitative analysis also suggested
that LDX treatment vs MAS XR demonstrated greater
numerical improvements in ADHD core and global
symptoms, as well as decreased frequency of percent dif-
ferences (active treatment minus placebo) in AEs. Al-
though exploratory in nature, these data suggest that
there may be within-class efficacy and safety differences
among psychostimulants; however, prospective and
quantitative head-to-head comparison trials are needed
to confirm these findings.
Findings from clinical trials have not provided clinicians
with sufficient comparative data to adequately assess which
psychostimulant may be optimal for individual patients,
especially since large variations in response rates to drugs
and doses exist, and the best sequence of dispensing the
various psychostimulant treatments by the clinician is cur-
rently unknown [34]. Studies such as the present analysis
may prove beneficial to clinicians in determining appropri-
ate treatment options after nonresponse or suboptimal
response to a particular psychostimulant therapy.
Overall, the safety profile of LDX was consistent with
other long-acting psychostimulants. The frequency of
common TEAEs ≥5% appeared to be lower in the LDX-
treated prior AMPH groups compared with the overall
population, perhaps because these patients were accli-
mated to the effects of psychostimulant medications.
This effect was also seen in a pediatric study of LDX
with patient groups that were previously treated with
psychostimulants [35].
Limitations of this analysis include results that may
not be representative of large cohorts because of the
small subgroup sample sizes and the study design fea-
tures discussed below. Since analyses were not designed
or powered to assess group differences and were described
with summary statistics, prospective studies are needed
to confirm these results. The majority of participants
were non-Hispanic/non-Latino, white, and moderately to
markedly ill at baseline; results may not be able to be
generalized to other ethnicities, races, or global illness
severity levels. Due to the post hoc nature of this
analysis, factors related to prior use of AMPH were not
controlled or assessed in the study: despite the know-
ledge that adequate mean doses of prior AMPH were
used, there was no information to determine if thesedoses were clinically optimized; data on the level of
compliance with prior AMPH treatment were also
lacking; and individuals with poor tolerability to AMPH
would be ineligible to participate in this study, presenting
another study limitation. The baseline symptom severity
before AMPH treatment was unspecified. In addition,
there was no apparent limitation on study enrollment
that would exclude participants with sufficient clinical
response to prior medication, since symptomatic non-
remitters on prior AMPH were not defined by overall
clinical response to AMPH, but only by the partici-
pant’s screening ADHD-RS-IV total score.
Conclusions
Overall, the analyses provide a signal suggesting that, for
patients who are not optimally treated with AMPH for-
mulations, LDX remains a potential alternative to con-
sider for the treatment of ADHD in adults. In addition,
efficacy outcomes in the prior AMPH subgroup popula-
tion were consistent with those of the overall study
population. The LDX safety profile was consistent with
long-acting psychostimulant use. However, this study
was not designed to address or compare relative advan-
tages and disadvantages of particular pharmacotherapeu-
tic alternatives. Prospective trials assessing this signal
would be helpful in determining the utility of such
options in clinical management of patients requiring
treatment changes.
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